Figure 1 shows an analytic framework, i.e., a graph that depicts key questions one and two. Briefly, patients with pediatric malignant solid tumor can be treated with HSCT or other therapies. The short term effectiveness and safety of the interventions is measured by intermediate outcomes (recurrence free survival and progression free survival) and adverse event data. The long term effectiveness and safety of the interventions is measured overall survival, long term consequences of HSCT, and quality of life.

Figure 1Analytic framework for HSCT for pediatric malignant solid tumors

HSCT = hematopoietic stem-cell transplantation; KQ = Key Question; QOL = quality of life

From: Introduction

Cover of Hematopoietic Stem-Cell Transplantation in the Pediatric Population
Hematopoietic Stem-Cell Transplantation in the Pediatric Population [Internet].
Comparative Effectiveness Reviews, No. 48.
Ratko TA, Belinson SE, Brown HM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.